X Chromosome Dosage Sensitivity Drives Age‑Dependent Heterochromatin Remodeling that Modulates Longevity

Background

The X chromosome contributes to lifespan beyond sex determination. In mice, XX individuals outlive XY counterparts independent of gonadal sex [1]. About 15 % of X‑linked genes escape inactivation in females, providing bi‑allelic expression that buffers deleterious mutations [2]. Aging reshapes X biology: hippocampal neurons show new escape of genes such as Plp1, bolstering myelin and cognition [4], and elevating Plp1 via AAV improves function in both sexes [5]. Human centenarians display balanced X‑inactivation, whereas skewing correlates with accelerated aging [6]. Conversely, age‑related loss of the Y chromosome in men links to cardiovascular disease and cancer [8].

Hypothesis

We propose that the longevity advantage of XX dosage stems from a dosage‑sensitive heterochromatin barrier on the inactive X that erodes with age, allowing stochastic escape of protective genes. In XY cells the single active X lacks this barrier, leading to earlier loss of heterochromatin integrity and premature expression of deleterious alleles. The barrier is mediated by a dosage‑dependent recruitment of the histone methyltransferase SETDB1, which spreads H3K9me3 across the inactive X. When XX cells retain two copies of the regulatory lncRNA Xist and its associated partners, SETDB1 activity is doubled, maintaining a more compact heterochromatin landscape. With advancing age, declining NAD+ reduces SIRT1 activity, weakening SETDB1 recruitment and triggering focal escape. The escaped transcripts include not only known escapees like Plp1 but also cryptic promoters that produce non‑coding RNAs enhancing DNA repair. Thus, the XX genotype provides a temporally extended window of heterochromatin protection that delays the onset of aging‑related transcriptional noise.

Predictions

1. In female mouse fibroblasts, SETDB1 occupancy on the inactive X will be ~2‑fold higher than in male fibroblasts at young age and will decline with age in both sexes, but the decline will be slower in XX cells.
2. Inducing a second copy of Xist in male embryos (XXY) will rescue SETDB1 levels and extend lifespan to match XX controls, whereas deleting one Xist allele in females will recapitulate the XY lifespan profile.
3. Pharmacological elevation of NAD+ (e.g., with NR) in aged XY mice will increase SETDB1 binding, reduce ectopic X‑linked transcription, and improve healthspan metrics.
4. Single‑cell RNA‑seq of aged human blood will show a higher variance of X‑linked expression in males compared with females, and this variance will correlate with clinical frailty indices.

Experimental Approach

• Generate mouse lines with inducible Xist copy number alterations (one, two, three copies) and measure lifespan, SETDB1 ChIP‑seq on the inactive X, and RNA‑seq escape profiles across the lifespan.
• Treat aged XY mice with nicotinamide riboside (NR) or vehicle, perform SETDB1 CUT&RUN, and assess escapee gene expression and functional endpoints (grip strength, cognitive testing).
• Analyze publicly available single‑cell transcriptomic datasets from human aged donors (e.g., GTEx, BLSA) to compute X‑linked expression variance and test its association with age‑related phenotypes.
• Use CRISPRi to silence candidate escapee promoters that emerge with age and evaluate impact on DNA‑damage markers (γH2AX) in vitro.

If SETDB1 dosage directly scales with X chromosome copy number and its loss precipitates the transcriptional drift that underlies sex differences in lifespan, then manipulating Xist copy number or NAD+ levels should decouple longevity from gonadal sex. Conversely, if lifespan differences persist despite equalizing SETDB1 activity, the hypothesis would be falsified, prompting a search for alternative X‑linked mechanisms.